MATERIALS, METHODS AND PATIENT INFORMATION
MATERIALS 1,5-Anhydro-D-glucitol and 1,5-anhydro-D-fructose were from Carbosynth, Berkshire, UK; 2-[ 3 H]-glucose was from American Radiolabeled Chemicals (ARC), Saint Louis, MO, USA; sodium [ 3 H]borohydride was from PerkinElmer, Boston, MA, USA; Sodium borodeuteride was from Sigma-Aldrich, Saint Louis, MI, USA; yeast hexokinase (1500 U/ml), Leuconostoc mesenteroides glucose-6-phosphate dehydrogenase (1000 U/ml), Lactobacillus leichmannii D(-)-lactate dehydrogenase (5 mg/ml) and rabbit muscle pyruvate kinase (10mg/ml) were from Roche Applied Science GmbH, Mannheim, Germany.
METHODS
Cell culture media HAP1 cells were cultured in IMDM (BioWhittaker, Lonza, Verviers, Belgium) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine and penicillin/streptomycin (Life Technologies) (designated as 'complete IMDM medium' below). For LC-MS, GC-MS and survival assays they were cultured in DMEM containing 1 g/l of glucose (BioWhittaker, Lonza, Verviers, Belgium), 10% FBS, 2 mM L-glutamine and penicillin/streptomycin (Life Technologies) (designated as 'complete DMEM medium' below).
Conditionally immortalized (ER-Hoxb8) and estrogen-dependent neutrophil progenitors obtained from G6PC3-deficient or wild-type mice were previously described (1) . They were cultured in Opti-MEM GlutaMAX (Life Technologies) containing 10% FBS, 30 µM 2-mercaptoethanol (Sigma-Aldrich, GmbH, Germany), 10 ng/ml SCF (Miltenyi Biotec, GmbH, Germany) and 1 µM beta-estradiol (Sigma-Aldrich, GmbH, Germany) (designated as 'complete Opti-MEM medium' below). When indicated 1,5AG or 1,5-anhydrofructose were added to the medium at appropriate concentrations.
Cloning, expression and preparation/purification of the protein extracts containing the recombinant enzymes G6PC1 and G6PC3
The coding sequences of human G6PC1 and human G6PC3 were PCR-amplified from human liver cDNA and inserted in the vectors pEF6/Myc-His A or pEF6/His B, which allow addition of a C-terminal and N-terminal 6xHis tag, respectively. Plasmids for the expression of untagged proteins were derived from the pEF6/Myc-His A plasmids. We also prepared the equivalent plasmids carrying a mutation replacing the highly conserved catalytic histidine (His176 in G6PC1; His167 in G6PC3) by an alanine as catalytically dead negative controls in phosphatase activity measurements. Primers used for PCR amplification or mutagenesis and the restriction enzymes used for cloning are provided in Table S3 . Once clones were obtained, all plasmids used in experiments to produce recombinant proteins were checked by sequencing. The above mentioned plasmids were transfected in HEK293T cells using jetPEI® as a transfection agent as described previously (2) . Cells were collected after 48 h from 10 cm diameter culture dishes. Under the conditions we used, the overexpression of proteins in the endoplasmic reticulum of HEK293T cells increases the number of cells that detach from the culture dish. To maximize the amount of recombinant protein recovered, we therefore collected both the cells attached to the culture dish, by washing with PBS and scraping it in 0.5 ml/plate of lysis buffer (25 mM Hepes pH 7.2, 2 µg.ml -1 antipain and leupeptin, 0.5 mM PMSF and 10% glycerol), as well as the detached cells, recovered by centrifugation of the media for 5 min at 800 g at 4°C), subsequent washing of the pellet with 5 ml PBS (centrifugation 5 min at 800 g at 4°C) and pooling of the collected cells with the ones recovered by scraping in lysis buffer. Cells were then lysed by 2 cycles of freezing-thawing in liquid nitrogen, treated with DNAse (0.1 mg.ml -1 in 10 mM MgSO 4 ) and centrifuged (15000 g for 15 min at 4°C) to recover a membrane fraction containing the recombinant proteins. The resulting pellet was washed twice by centrifugation as above with the same volume of lysis buffer and the resulting pellet was concentrated 2-fold by resuspension in half of the initial volume of lysis buffer used. This preparation was aliquoted (0.2 ml) and kept stable at -80°C to be used as an enzyme source. ADP-glucokinase (ADPGK), Hexokinase 1 (HK1), Hexokinase 2 (HK2) and Hexokinase 3 (HK3): All three human hexokinases and ADPGK were cloned in pET28a with a N-terminal 6xHis tag. For HK1 and HK2 the tag replaced the mitochondrial porin binding sequence (HK1: Met1 to Lys21; HK2: Met1 to His28) and for HK3 the full coding sequence was cloned. In the case of ADPGK the tag replaced the hydrophobic N-terminal region that binds to endoplasmic reticulum (Met1 to Pro50) (3) . All plasmids were checked by sequencing before being used to transform E. coli BL21(DE3) to express the hexokinases or E. coli Rosetta-gami™ 2(DE3) to express ADPGK. Protein expression was induced by addition of 0.4 mM IPTG once A600 had reach 0.6 U. Hexokinases were expressed at 20°C for 48h in 400 ml of M9 medium (HK1 and HK3) or LB medium (HK2), and ADPGK at 30°C for 20h in LB medium. Bacterial extracts were prepared in 20 ml lysis buffer (25 mM Hepes, pH 7.2, 5 µg.ml -1 antipain and leupeptin, 0.5 mM PMSF and 1 mg.ml -1 lysozyme) and recombinant proteins present in the soluble fraction were purified by metal-affinity chromatography (HisTrap HP columns -1 ml) as previously described (4) . The purified fractions were desalted on a PD-10 column (GE Healthcare) equilibrated with a solution containing 25 mM Hepes, pH 7.2, 500 mM NaCl, 1 mM dithiothreitol (DTT), 10% glycerol and stored at -70 °C until use. Sequence of primers used for cloning and mutagenesis are shown in Table S3 .
Western blot analysis for quantification of expression of recombinant G6PC1 and G6PC3 in HEK293T membrane preparations
Expression of all 6xHis tagged proteins was quantified by Western blot analysis. We measured protein concentration in membrane preparations of HEK293T cells overexpressing G6PC3 and G6PC1 using the Bradford assay (5) and bovine serum albumin (BSA) as a standard. Equal amounts (10 µg/well) of each preparation were loaded on an SDS-PAGE gel for comparison of the expression levels by western blotting using monoclonal anti-His antibody (GE Healthcare) and penta-His antibody (Qiagen) to detect N-and C-terminally tagged G6PC1s and G6PC3s, respectively. Quantification of the signals was achieved using a luminescent image analyzer ImageQuant 4000 (GE Healthcare).
Assay of phosphatase activity of human recombinant G6PC3 and G6PC1
The phosphatase activity of the G6PC1 and G6PC3 preparations was assayed by measuring the release of inorganic phosphate after incubating the enzyme preparations for 10 min at 30°C in the presence of the indicated substrates (all tested at 100 µM). To ensure linearity in the reaction during the incubation period, protein concentrations in the assay were adjusted depending on the enzyme and the substrate tested (G6PC1: 0.05 mg.ml -1 for glucose-6P, mannose-6P and inorganic pyrophosphate; 0.11 mg.ml -1 for 1,5AG6P; 0.23 mg.ml -1 for the other substrates; G6PC3: 0.05 mg.ml -1 for all substrates) so that no more than 35 % of the substrate was consumed at the end of the incubation.
Incubations were performed for 10 min at 30°C in 50 mM cacodylate, pH 5.8, 2 mM EDTA, 0.25 mg.ml -1 BSA, 2.5 mM octylglucoside, in a final volume of 50 µl. The reaction was stopped by addition of HCl (5 µl 2 M) and inorganic phosphate released was determined in 96 well plate with 45 µl of the reaction mixture, 35 µl H 2 O and 150 µl of Malachite green solution (6) . A standard curve with known concentrations of inorganic phosphate was always run in parallel.
To account for any phosphatase activity that might be present in the protein preparations used and that was not contributed by G6PC1 or G6PC3, we also transfected appropriate controls corresponding to similarly expressed but catalytically dead G6PC1 or G6PC3 proteins in parallel experiments. Phosphatase activities observed in these control samples were subtracted from the corresponding wild type samples.
Preparation of microsomes and assay of enzymatic activities
Tissue microsomes (liver, spleen, heart and skeletal muscle) were prepared from overnight fasted male Wistar rats (≈ 250 g) as previously described (7) . Briefly, fresh tissues were homogenized in a Potter-Elvehjem homogenizer with 3 volumes (v/w) of 25 mM Hepes pH 7.1, 25 mM KCl, 250 mM sucrose and 2.5 µg.ml -1 each leupeptin and antipain. In the case of skeletal muscle and heart, these tissues were minced on ice with the help of sharp scissors before homogenization. The homogenates were centrifuged for 20 min at 18 000 g and the resulting supernatants were centrifuged for 60 min at 80 000 g and 4°C. Resulting pellets were resuspended in the initial volume of homogenizing buffer with the help of Dounce homogenizer, and centrifuged again at 80 000 g as above. The pellets containing the microsomal preparation were finally resuspended with a Dounce homogenizer in 0.2 ml of the homogenizing buffer per g of initial tissue and stored at -80°C in 50 µl aliquots until used. Protein concentration was measured using the Bradford assay (5) and BSA as a standard.
To determine the substrate specificity of the phosphatase(s) endogenously present in tissue microsomes, phosphatase activities were measured with a radiochemical assay in the presence of 10 µM [ 12 C+ 14 C]-U-glucose-6-P or [ 12 C+ 14 C]-U-ribose-5-P in 50 µl of an assay mixture containing 50 mM cacodylate, pH 5.8, 2 mM EDTA, 7.5 mM octylglucoside, and 250 mM sucrose. Protein concentrations used in the assay varied depending on the tissue and the substrate tested to ensure linearity of the reaction during the incubation period. The reaction was stopped after 30 min at 30°C by heating the mixture for 5 min at 80°C, diluting it 20-fold with H 2 O, pelleting the proteins and loading the supernatant on 1 ml DOWEX AG1-X8 (Clform) columns equilibrated in H 2 O. Dephosphorylated reaction products were not retained in the column and were recovered in the flow-through and a 4 ml wash with H 2 O. Both were pooled, quantified by scintillation counting and used to calculate the phosphatase activity present in the preparations tested. Blanks were run without addition of microsomes to the assay mixture.
To determine the dependence of substrate transport on G6PT (= SLC37A4), we tested the sensitivity of substrate hydrolysis to S3483, a specific inhibitor of G6PT. Phosphatase activity was measured in skeletal muscle microsomes with 100 µM glucose-6-, 1,5AG6P, ribitol-5-P, ribose-5-P, and inorganic pyrophosphate, in the presence or absence 100 µM S3483 and with or without 7.5 mM octylglucoside. As for the measurement of the phosphatase activity of recombinant G6PC3 and G6PC1, the microsomes needed to be appropriately diluted in the assay to ensure linearity of the reaction during 30 min at 30°C so that no more than 35 % of the substrate was consumed. Therefore, the preparation of microsomes (12.3 mg.ml -1 ) was diluted 20-, 35-, 50-or 200-fold in the assay mixture when hydrolysis of glucose-6-P, 1,5AG6P, ribose-5-P and ribitol-5-P or inorganic pyrophosphate was measured.
In both assays, 50 µl reactions were arrested by the addition of 5 µl of 2 M HCl and kept on ice until measurement of Pi release. For this, the samples were quickly centrifuged to remove protein and 45 µl of the supernatant was used for inorganic phosphate assay as described above. Blanks in which the microsomes were added only after addition of HCl were used as controls.
Assay of hexokinases and ADPGK activity on glucose and 1,5AG, and their inhibition by 1,5AG6P
Hexokinases activity on glucose was assayed spectrophotometrically in a coupled assay with glucose-6-phosphate dehydrogenase, which prevents accumulation of glucose-6-P in the assay mixture (and therefore inhibition of hexokinase activity) and couples glucose-6-P formation to the reduction of NADP and an increase in absorbance at 340nm. The reaction was measured continuously at 30°C in a 1 ml cuvette containing 25 mM Hepes, pH 7.2, 25 mM KCl, 5 mM MgCl 2 , 0.5 mg.ml -1 BSA, 0.3 mM NADP, 1 mM dithiothreitol (DTT), 0.5 mM ATP-Mg, variable concentration of glucose and 1 unit.ml -1 desalted L. mesenteroides glucose-6P dehydrogenase. The reaction was started by the addition of hexokinase. To assess the inhibition of hexokinases by 1,5AG6P we used the same assay in the presence of variable concentrations of 1,5AG6P (between 20 and 100 µM depending on the hexokinase tested) that we produced in our lab (see below in SI Material and Methods). Ki values were estimated using Graphpad Prism. After entering data, the results were fitted using a nonlinear regression analysis, the panel of enzyme kinetics equations, and the noncompetitive enzyme inhibition. Hexokinases' activity on 1,5AG was also assayed spectrophotometrically by using a different assay, since glucose-6P dehydrogenase does not oxidize 1,5AG6P. Instead, we measured ADP production using a pyruvate kinase/lactate dehydrogenase-coupled assay described in (8) at 30°C using the same assay mixture as above, but with the appropriate coupling enzymes, 0.3 mM NADH, 0.25 mM phosphoenolpyruvate and the required concentrations of 1,5AG. During these measurements, since hexokinases have a very low affinity for 1,5AG (see Table 1 ), we needed to add high concentrations of 1,5AG and noticed that some stocks were contaminated by glucose. Since glucose interfered with this assay, care was taken to use a stock of 1,5AG that was free from glucose. ADPGK activity on glucose was measured both spectrophotometrically using the glucose-6P dehydrogenase coupled assay described above but also with a radiochemical assay, where we measure the production of [ 12 C+ 14 C]-glucose-6P from [ 12 C+ 14 C]glucose, as it was the case for the results shown in Table 1 . Of note, both methods gave very comparable results. In the radiochemical assay, the 100 µl assay mixture contained 25 mM Hepes, pH 7.2, 25 mM KCl, 5 mM MgCl 2 , 0.5 mg.ml -1 BSA, 1 mM dithiothreitol (DTT), 1 mM ADP-Mg, ≈ 50 000 cpm of [ 14 C]-U-glucose and variable concentrations of glucose. The reaction was started by adding purified recombinant human ADPGK (typically 0.2 µg.ml -1 ) to the pre-warmed mixture and stopped after 10 min by heating the tubes for 5 min at 80°C. The mixture was diluted 10-fold with H 2 O, 30 µl were used to measure total radioactivity and 950 µl were loaded on a 1 ml DOWEX AG1-X8 column (Clform) equilibrated in H 2 O. The column was washed with 4 ml of H 2 O, to remove the unbound radioactivity (i.e. [ 12 C+ 14 C]-U-glucose), and radioactivity that remained bound to the column (i.e. [ 12 C+ 14 C]-glucose-6P) was eluted with 4 ml of 0.3 M NaCl, counted and used to calculate ADPGK activity. Blanks were run without addition of ADPGK to the assay mixture. To test whether 1,5AG6P inhibited ADPGK, we used the same assay in the presence of increasing concentrations of 1,5AG6P (up to 1 mM). ADPGK activity on 1,5-AG was measured using a radiochemical assay similar to one described above for glucose but where [ 12 C+ 14 C]-glucose was replaced by 2-[ 1 H+ 3 H]-1,5AG that was produced in our the lab (see SI Materials and Methods). The incubation mixture was the same, except that we used ≈ 30 000 cpm of 2-[ 3 H]-1,5AG, variable concentrations of 1,5AG and typically 3 µg.ml -1 ADPGK. The reaction product 2-[ 1 H+ 3 H]-1,5AG6P was isolated, the radioactivity was counted and the values were used to compute ADPGK activity as described above. When shown, K M and V max values were estimated using Graphpad Prism. After entering data, the results were fitted using a nonlinear regression analysis, the panel of enzyme kinetics equations, and the Michaelis-Menten enzyme kinetics.
Synthesis of 2-[ 3 H]-1,5-anhydroglucitol, 2-[D]-1,5-anhydroglucitol (deuterated), 2-[D]-1,5-anhydroglucitol-6-P (deuterated) and 1,5-anhydroglucitol-6-P
Radiolabelled 2-[ 3 H]-1,5AG was produced by reduction of 1,5-anhydrofructose with sodium [ 3 H] borohydride. Practically, we incubated 200 µl of 1 mM 1,5-anhydrofructose with 5 x 10 8 cpm of sodium [ 3 H] borohydride (11.2 Ci/mmol) for 90 min at 25°C. To get rid of the remaining borohydride we added 0.1 ml of 10% (w/v) HClO 4 and left the sample for 60 min at 25°C, after which it was neutralized with 3M KOH/KHCO 3 and kept on ice for 5 min. Since during the reduction step with sodium [ 3 H] borohydride, 1,5anhydrofructose was reduced to both 2-[ 3 H]-1,5AG and 2-[ 3 H]-1,5-anhydromannitol, we needed to isolate 2-[ 3 H]-1,5AG. To do this, we phosphorylated the sample containing both radiolabeled compounds with ADPGK, which only phosphorylates 1,5-AG. The phosphorylation proceeded as follows: 270 µl of the radiolabeled sample were incubated in 1 ml reaction mixture containing 25 mM Hepes pH 7.2, 2 mM ADP-Mg, 5 mM MgCl 2 , 1 mM DTT, 0.5 mg/ml BSA and 15 µg of purified human recombinant ADPGK prepared in our lab (SI Materials and Methods). After 2 h at 30°C, the reaction was stopped (5 min at 80°C), the sample centrifuged and the supernatant diluted to 3 ml with H 2 O before being applied on an 1 ml DOWEX AG1-X8 ion exchange column (Clform). Washing the column with 10 ml of H 2 O removed 2-[ 3 H]-1,5-anhydromannitol. The remaining 2-[ 3 H]-1,5AG6P bound to the column was eluted with 0.2 M NaCl in 2 x 1 ml fractions (≈ 40% of the total radioactivity loaded on the column). Eluates were treated for 60 min at 37°C with 40 U (2 x 1 µl every 30 min) of intestinal calf alkaline phosphatase in 10 mM Tris, pH 8.5 (Roche Applied Sciences). The reaction was arrested by heating for 5 min at 80°C, centrifuging (5 min at 16000 g), recovering the supernatant and heating and centrifuging once again as before, to prevent contamination of the sample by alkaline phosphatase. To verify that all the radiolabeled 2-[ 3 H]-1,5AG6P had been converted to 2-[ 3 H]-1,5AG, we loaded an aliquot of the sample on a DOWEX AG1-X8 (Clform) column. More than 97% of the total radioactivity did not bind to the column. 2-[ 3 H]-1,5AG was aliquoted (0.1 ml), stored at -80°C and used in the radiochemical assay of the activity of ADPGK or other kinases on 1,5AG. 1,5AG6P was produced by phosphorylation of 1,5AG with yeast hexokinase (Roche Applied Science), which is neither inhibited by glucose (as ADPGK is) nor by 1,5AG6P as mammalian hexokinases are (see Table 1 ). Practically, we prepared 1.5 ml of the following reaction mix: 25 mM Hepes, pH 7.2, 20 mM 1,5AG, 18 mM ATP-Mg, 5 mM MgCl 2 , 25 mM KCl and 1 mM DTT, and filter-sterilized it. We then added 0.2 ml of desalted yeast hexokinase (120 Units) to 1.3 ml of the sterile reaction mix and incubated it for 15 h at 30°C. The reaction was stopped (5 min at 80°C), centrifuged (5 min at 16000 g) and the 3-fold diluted supernatant (≈ 4.5 ml) was loaded on a 1 ml DOWEX AG1-X8 ion exchange column (Clform). Compounds that did not bind to the column were removed by washing with water (5 ml) and 1,5AG6P was eluted from the column with 0.2 M NaCl (2 x 1 ml). The precise concentration of 1,5AG6P in each fraction could be determined by measuring the production of inorganic phosphate (6) following incubation of an aliquot of each fraction with alkaline phosphatase. Baseline 1,5AG6P in each fraction corresponded to the inorganic phosphate found in a similar aliquot incubated in the absence of alkaline phosphatase. This procedure resulted in the phosphorylation of close to 90% of the 1,5AG in the initial reaction mixture to 1,5AG6P.
Production and culture of HAP1 cell lines deficient in G6PT and G6PC3 CRISPR/Cas9 plasmids driving the expression of single guide RNAs were generated to inactivate the genes coding for G6PT/SLC37A4 and G6PC3. Plasmids were prepared by ligating annealed pairs of primers shown below into the vector pSpCas9(BB)-2A-Puro (PX459) (a gift from F. Zhang, Massachussetts Institute of Technology; Addgene plasmid no. 48139) (9) digested by BbsI. The G6PC3 gene was targeted in two different regions. Target 1 targeted exon 4 containing the catalytic His167 and resulted in clone G6PC3-D7 while Target 2 targeted the ATG region and resulted in clone G6PC3-A6. The G6PT gene was targeted only in one region comprising exon 4 and resulted in clone G6PT-A4.
Pairs of primers annealing in G6PC3-Target 1:
Pairs of primers annealing in G6PC3-Target 2: CRISP-hG6PC3-T2-s1 CACCGgcgctacagaaccagctagcc CRISP-hG6PC3-T2-as1 AAACggctagctggttctgtagcgcC CRISP-hG6PC3-T2-s2 CACCGgcccagcgtggactccatgg CRISP-hG6PC3-T2-as2 AAACccatggagtccacgctgggcC Pairs of primers annealing in G6PT: CRISP-hG6PT-s1 CACCGgctgaccagatgagtgctcgc, CRISP-hG6PT-as1 AAACgcgagcactcatctggtcagcC CRISP-hG6PT-s2 CACCGgataagctgccgactggctgc CRISP-hG6PT-as2 AAACgcagccagtcggcagcttatcC All constructs were validated by sequencing. HAP1 cells were transfected with the CRISPR/Cas9 constructs and transiently selected with puromycin as described in (10) . Genomic DNA from puromycin-resistant clones was used to PCR-amplify the regions surrounding the targeted sites and the PCR products were sequenced to assess any genetic modification present in each clone. The HAP1 clones used in these study had the following mutations: G6PT-A4 : change of reading frame after Gly50 leading to a premature stop codon;
G6PC3-A6 : 32 pb deletion encompassing the initiator ATG; G6PC3-D7 : 48 bp deletion after Leu155 leading to a premature stop codon.
Metabolite analysis in HAP1 cells
HAP1 cells were seeded in 6-well plates (at 0.8 x 10 6 cells/well) and incubated in 2 ml of 'complete DMEM medium' (see above) in the absence or presence of 0.1 or 1 mM 1,5AG or 0.05 or 0.5 mM 1,5-anhydrofructose for 20 h. At this time the medium was replaced with prewarmed fresh medium containing the appropriate concentration of 1,5AG or 1,5anhydrofructose, and the old medium was kept to determine glucose concentration. The incubation was continued for 4 h. To quench metabolic activity, the medium was removed, plates were washed rapidly with ice-cold water, and plunged in liquid nitrogen (11) . To the still frozen plates, 250 µl of a 90 % methanol/10 % chloroform mixture was added. The cells were scraped, collected and the extracts centrifuged (16000 x g during 15 min at 4°C). The supernatants were analysed by LC-MS. LC-MS analysis was performed using a method similar to the one described by Coulier and colleagues (12) . The chromatographic separation was performed on an Agilent 1290 HPLC system using an Inertsil 3 µm particle ODS-4 column (150 x 2.1 mm; GL Biosciences) at a constant flow rate of 0.2 ml/min with mobile phase A consisting of 5 mM hexylamine (Sigma-Aldrich, USA) adjusted to pH 6. ]forms were integrated using MassHunter software (Agilent, Santa Clara, CA, USA), and areas were normalized to total ion current. LC-MS results were obtained in three independent experiments. Within each experiment, the normalized value for the untreated condition for each cell line was set to 100%. Data is shown as means ± SD across three experiments.
GC-MS analysis was performed as described in Collard et al. (10) . For 1,5AG we used 217 and 191, and for 1,5AG6P we used 362 and 315 as quantifier and qualifier ions, respectively.
Of note, in these experiments, the elution times for hexose phosphates partially overlap with the elution time of 1,5AG6P. While these compounds are easily separated based on their mass in normal samples, a low-abundance in-source oxidation product of 1,5AG6P (with the same mass as hexose phosphates) confounds the quantification of hexose phosphates in samples with very high concentrations of 1,5AG6P. Thus, we preferred to show hexose bisphosphate concentrations to demonstrate reduced concentrations of upper glycolytic intermediates in Fig. 2E . In any case, GC-MS analysis clearly demonstrates that glucose-6P and fructose-6P concentrations decrease in HAP1 cells under conditions when 1,5AG6P accumulated ( Fig. S2 .E-F; H-I).
Measurement of glucose consumption in HAP-1 cells
To determine glucose consumption in HAP-1 cell lines, we measured the glucose concentration remaining in the medium after 20 h using a spectrophotometric assay. Practically, the samples were deproteinized by addition of HClO 4 (5% final) to 0.2 ml of the medium, centrifuged (5 min at 16 000 g) and neutralized with 3M KOH/KHCO 3 . The insoluble precipitate was removed by centrifugation (5 min at 16000 g). Glucose was measured in the supernatant in a 1 ml cuvette containing 0.1 M Tris, pH 7.4, 5 mM MgCl 2 , 0.3 mM NADP, 1 mM ATP-Mg, 50 µl of neutralized extract and 1.75 units desalted yeast glucose-6P dehydrogenase (Roche Applied Science). The reaction was started by addition of 1.5 units desalted yeast hexokinase. The concentration of glucose was determined by measuring the change in absorbance at 340 nm after the addition of hexokinase. Glucose consumption was calculated by comparing the glucose concentrations in the culture medium after 20 h with the one observed in fresh medium that was treated the same way.
Cell viability assays
Cell viability was measured using the CellTiter-Glo® Luminescent Cell Viability (Promega, Madison, USA) in HAP-1 cells and estrogen-dependent immortalized mouse G6PC3 deficient or wild-type neutrophil progenitors (ER-Hoxb8) (1).
HAP-1 cells (2500 cells/well) and ER-Hoxb8 mouse neutrophil progenitors cell lines (5000 cells/well) were seeded in an opaque-wall 96 well plate suitable for luminescence measurements in 100 µl of appropriate media (HAP-1 cells: 'complete DMEM medium' -1 g/l glucose; neutrophil progenitors cells: 'complete Opti-MEM medium' -3 g/l glucose) with or without addition of 1,5AG (0 -2 mM) or 1,5anhydrofructose (0 -1 mM). After 72 h, we added 100 µl of the reconstituted CellTiter-Glo® Substrate to each well, gently agitated the plate for 20 min and measured luminescence using a 96-well luminometer (Promega GloMax®) according to the manufacturer's instructions.
Glucose detritiation assays
Glycolytic glucose utilization in estrogen-dependent immortalized mouse G6PC3deficient or wild-type neutrophil progenitors (ER-Hoxb8) (1) was indirectly evaluated by measuring the detritiation of 2-[ 3 H]-glucose (which occurs at the phosphoglucose isomerase level) (13) in cell cultures grown in the presence or absence of 0.2 mM 1,5AG. Practically, wild-type and G6PC3 deficient ER-Hox8b mouse neutrophil progenitors (0.65 x 10 6 cells/ml) were plated in 'complete Opti-MEM medium', in 12-well plates (1.25 ml/well) containing or not 0.2 mM 1,5AG and 2-[ 3 H]-glucose (≈ 0.5 x 10 6 cpm/ml). Medium without cells was used for time = 0 and as the baseline signal for the 4 and 8 h time points. At the indicated time points, metabolism was arrested by addition of 60% HClO 4 (5% final) to 1.2 ml of the cell suspension. After centrifugation to remove proteins and neutralization of the supernatant with 3M KOH/KHCO 3 , the preparation was diluted to 3 ml and 2.8 ml were chromatographed on a Dowex AG1X8 (borate form) column (1 ml) to separate 3 H 2 O from the tritiated 2-[ 3 H]-glucose that remained bound to the column. By comparing the radioactivity corresponding to the 3 H 2 O that was formed in each sample with the total radioactivity present in that sample (measured in a 100 µl aliquot), we calculated the proportion of 2-[ 3 H]-glucose that had been detritiated.
Generation and analysis G6PC3 deficient mice
Animal procedures were approved by the Université Catholique de Louvain Research Ethical Committee. G6PC3 KO mice were created using the CRISPR/Cas9 genomeediting system as previously described (14) using the vector pX330-U6-Chimeric_BB-CBh-hSpCas9 (a gift from F. Zhang, Massachusetts Institute of Technology; Addgene plasmid no. 42230) (9) . The sequences of two single guide RNAs were chosen to target regions in exon 4 of the mouse G6PC3 gene that were separated by ≈ 90bp. The two plasmids expressing the single guide RNAs pX330-mG6PC3-1 and pX330-mG6PC3-2 were prepared by ligating the annealed primer pairs shown below into the vector pX330 digested by BbsI and sequenced to exclude any errors.
Pairs of primers annealing to the target sequence of the mouse G6PC3 gene cloned in:
These single guide RNAs were chosen in a larger selection of single guide RNAs based on their superior capacity to cleave the target site of the G6PC3 gene cloned in the pCAG-EGxxFP vector (gift from Ikawa Mashiko; Adgene plasmid number 50716) (15) . Both plasmids were co-microinjected into the pronuclei of one-cell-stage embryos derived from C57BL/6N mice.
Mice carrying mutations were genotyped by PCR analysis using primers that encompass the mutated region. Two mouse lines with distinct mutations were retained for further analysis. A 90 bp deletion (strain G6PC3-904) removed the catalytic histidine (H167), while the other mutation (strain G6PC3-912) caused an 8 bp deletion after the Pro120 codon, leading to a change in reading frame and a premature stop codon. Both mouse strains were equally neutropenic. Experiments were performed mostly with the G6PC3-904 strain. Homozygous knockout mice were compared to heterozygous littermates, which could be used as controls since they are not neutropenic.
Mice (≈ 28 g for males; ≈ 21 g for females; ≈ 3 month old) were gavaged with 100 µl suspension of Empagliflozin in 0.9% NaCl so that each animal received 10 mg.Kg -1 of body weight. The Empagliflozin suspension was made by crushing a 10 mg tablet of Jardiance® (Boehringer) and resuspending the powder in the appropriate volume of saline. 1,5AG was equally administered by gavage (100 µl of a 50 mM solution). The protocol for Empagliflozin and 1,5AG administration is specified in the figure legends illustrating the results from the experiments shown. Control mice were either untreated or gavaged with 100 µl 0.9 % NaCl, as specified in the figure legends.
Repeated blood-draws were performed from the mouse tail to determine the serum concentration of 1,5AG (10-15 µl) by LC-MS or to assess neutropenia by flow cytometry (25 µl). At the end of the experiment, blood (≈ 0.7 ml) was collected in EDTA tubes from the vena cava following euthanasia. It was used for flow cytometry analysis to evaluate granulocyte numbers (50 µl), for automatic cell counting and to recover white blood cells and plasma for LC-MS determination of 1,5AG6P and 1,5AG, respectively.
Total white blood cell counts were determined with a Sysmex XN1000 hematology analyzer and blood differentials were obtained by manual re-classification on a Sysmex Di60 digital microscope.
Mouse bone marrow was recovered from flushing one femur with PBS containing 10 mM EDTA. Slides were then dried and fixed with methanol before staining with May-Grünwald 50% dilution (pH 6) and 1/5 dilution of Giemsa (pH 6.7) (Merck, Darmstadt, Germany). Myeloperoxydase activity was assessed using a staining kit containing alphanaphtol and pyronin (RAL diagnostics, Martillac, France), staining peroxidase-positive granules in bright red. Pictures were taken with a BX43 microscope equipped with a MPLAN APO 100X objective and a DP26 digital camera (Olympus, Tokyo, Japan).
Flow cytometry assays
Mouse blood granulocytes were analyzed by flow cytometry as previously described (16) . In brief, 100 µl of whole blood collected in EDTA-tubes was diluted in 2 ml PBS (without Ca 2+ and Mg 2+ ), separated in two tubes (1 ml/tube) and centrifuged at 20°C (5 min at 400 g). The supernatant was immediately removed and the recovered pellet was stained with 50 µl of PBS + 2% FBS containing or not 0.25 µg of FITC-labeled Ly-6G (Gr-1) monoclonal antibody (clone RB6-8C5, eBioscience™, Invitrogen) and 0.12 µg of PE-labeled CD11b (Mac-1) monoclonal antibody (clone M1/70, eBioscience™, Invitrogen). Samples were incubated for 15 min in the dark. Red blood cells were lysed by adding 0.6 ml of red blood cells lysis buffer consisting of 155 mM NH 4 Cl, 10 mM KHCO 3 , 1 mM EDTA, adjusted to pH 7.2 (freshly made from a filter-sterilized 10-fold concentrated solution). After incubation for 20 min, data acquisition was on a flow cytometer (FACSVERSE, BD Biosciences) and data analysis using the FlowJo software package (FlowJo LLC, Oregon, USA).
Isolation of human leukocytes and quantification of 1,5-anhydroglucitol-6phosphate in human leukocytes
PMN leukocytes (consisting mostly of neutrophil granulocytes) present in 2.5 ml of freshly collected blood were separated from PBMC (peripheral blood mononuclear cells) by centrifugation on 2.5 ml Polymorphprep™ (AXIS-SHIELD, Oslo, Norway) following the manufacturer's instructions. Control cells behaved as expected, and a perfect separation of PMN from red blood cells was achieved. For unknown reasons, in the case of patients blood, PMN cells were always contaminated by a fraction of red blood cells that could not be pelleted. PMN cells and contaminating red blood cells were therefore resuspended in red blood cell lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , 1 mM EDTA, adjusted to pH 7.2) to purify PMN cells. After red blood cell lysis and centrifugation (10 min at 400 g), the purified PMN cells and the PBMC were washed by centrifugation in 0.9% NaCl (10 min at 400 g). To extract intracellular metabolites, the pellets were carefully resuspended in 1 ml (50% methanol/H 2 O) followed by addition of 1 ml chloroform and the metabolites were extracted by shaking the tubes for 40 min at 20000 rpm at 4°C in a horizontal shaker followed by centrifugation at 4°C (10 min at 16000 g). Metabolites present in the aqueous phase were recovered and kept at -80°C until analysis by LC-MS as described for HAP1 cells above.
To estimate absolute concentrations, each sample was typically spiked with 0.05 to 0.2 µM deuterated 1,5AG6P (2-[D]-1,5AG6P) as internal standard. These variable concentrations were necessary to account for the vastly different 1,5AG6P concentrations between samples and the limited isotopic purity (98.5 %) of our internal standard. Absolute concentrations in the cellular lysates were determined by comparing the integrated extracted ion chromatograms corresponding to 1,5AG (m/z = 163.0612) with the ones of the standard 2-[D]-1,5AG (m/z = 164.0674), taking into account the natural isotopomer distribution of 1,5AG and the isotopic purity of the synthesized 2-[D]-1,5AG. Since we knew the number of PMN cells or PBMC that were used to prepare the extracts, based on published intracellular volumes for PMN (17) and PBMC (18) we calculated the intracellular concentration of 1,5AG6P in PMN cells and PBMC. Of note, particularly for patients with lower neutrophil counts, we cannot exclude a small contamination of the PBMC fraction with the PMN cell fraction, which likely explains the variability observed in the ratio of 1,5AG6P found in PMN cells versus PBMC (4.3 to 13 -see results), for the three analysed patients (see Fig. 5A ).
LCMS analysis of 1,5AG6P in mouse white blood cells extracts
To prepare mouse white blood cells extracts, we centrifuged approximately 0.6 ml of whole blood collected in EDTA tubes, recovered the plasma and added ≈ 2 ml of red blood cell lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , 1 mM EDTA, pH 7.2) to approximately 0.6 ml of whole blood. After red blood cell lysis (≈ 15 min), the tubes were centrifuged (5 min at 600 g) and the pellet containing the white blood cells washed with 2 ml 0.9% NaCl and centrifuged as above. After removing the supernatant, the pellet was resuspended in 1 ml (50% methanol/H 2 O) followed by addition of 1 ml chloroform and the metabolites were extracted by shaking the tubes for 40 min at 20000 rpm at 4°C in a horizontal shaker followed by centrifugation at 4°C (10 min at 16000 g). The metabolites present in the aqueous phase were recovered and kept at -80°C until analysis by the same ion pairing LC-MS method as used for the analysis of HAP1 cells (see above). Extracted-ion chromatograms of the [M-H]forms were integrated using MassHunter software (Agilent, Santa Clara, CA, USA), and areas under the curve were normalized to total ion current. Data is shown as means ± SD across the indicated number of animals.
Quantification of 1,5-anhydroglucitol in mouse and human plasma by LC-MS
1,5AG in mouse and human plasma was quantified by LC-MS. Practically, we added 4 µl of plasma to 191 µl of (20% H 2 O/80% of a solution containing 90% methanol and 10% chloroform) and spiked it with 5 µl of 30 µM 2-[D]-1,5AG (0.75 µM final concentration), used as an internal standard. After centrifugation at 4°C (5 min at 16000 g) the supernatant was kept at -80°C until used for LC-MS analysis. LC-MS analysis was performed with a rapid version of the ion-pairing approach described above using a 5 µM ODS(2) InertClone column (100 x 4.6 mm, Phenomenex) and the same buffers as described above. The mobile phase profile consisted of the following steps and linear gradients: 0 -4 min at 0 % B; 4 -10 min from 0 to 100 %; 10 -15 min at 100 % B; 15 -16 min from 100 to 0 %; 16 -20 min at 0 % B. Flow rate was 0.5 ml/min between 0 and 4 min, and 1 ml/min for the remaining time. Mass spectrometric analysis was performed as described above, but absolute concentrations were determined by comparing the integrated extracted ion chromatograms corresponding to 1,5AG (m/z = 163.0612) with the ones of the standard 2-[D]-1,5AG (m/z = 164.0674), taking into account the natural isotopomer distribution of 1,5AG and the isotopic purity of the synthesized 2-[D]-1,5AG.
Targeted LC-MS analysis of mouse neutrophil progenitors cell lines (Hox8b)
Extracts were prepared by transferring 10 ml cell suspensions (n = 6) containing immortalized mouse G6PC3-deficient or wild-type neutrophil progenitors (ER-Hoxb8), cultured in 'complete Opti-MEM medium' with 0.2 mM 1,5AG, into 15 ml ice-cold tubes followed by immediate centrifugation at 4°C (3 min at 800 g), removing the media, snap freezing the pellets in liquid nitrogen and storage at -80 °C until extraction.
Metabolite extraction was achieved by adding an adjusted volume of extraction fluid (50 % methanol, 50 % TE buffer at pH 7.0 containing 10 mM TRIZMA and 1 mM EDTA, -20 °C) and chloroform (-20 °C) to the frozen cell pellets. The extraction volume was adjusted according to the cell concentration determined at the time of sample taking using a Countess Automated Cell Counter (ThermoFisher Scientific, Invitrogen) according to a ratio of 120 µl extraction fluid per 2x10 6 cells. Complete cell lysis was achieved by incubating the extraction mixture for 2 h on a shaking device (vortexer) at -20 °C. Cell debris were separated by centrifugation, and the upper aqueous layer of the two phase system was filtered through a 0.22 µm regenerated cellulose membrane (Phoenix).
The intracellular concentration of different groups of metabolites was measured by scheduled MRM LC-MS/MS on a Nexera XR LC 20AD (Shimadzu) coupled to an API400 Qtrap mass spectrometer equipped with an electrospray ion source (Sciex). Nitrogen was supplied by an NMG33generator (CMC). Absolute concentrations were calculated based on external calibration curves prepared in 50 % LC-MS-grade methanol. Measurement values were normalised to 13 C-labelled internal standards.
Intermediates of glycolysis and the target metabolite 1,5AG6P were separated by hydrophilic interaction liquid chromatography using a zwitter ionic column (SeQuant®ZIC®-HILIC, Merck) equipped with a precolumn (SecurityGuard ULTRA UHPLC HILIC, Phenomenex) at a temperature of 25 °C and a flow rate of 0.4 ml/min. Using solvent A (20 mM ammonium acetate in water) and solvent B (20 mM ammonium acetate in 90 % acetonitrile), the following gradient was applied: 0 -10 min, 90 -50 % B; 10 -11 min, 50 -20 % B; 12 -13 min, 20 % B; 13 -14 min, 20 -90 % B; 14 -20 min, 90 % B. The injection volume of standards and samples was 3 µl and uniformly labelled [ 13 C]-glucose-6-phosphate, [ 13 C]-fructose-1,6-bisphosphate, and [ 13 C]dihydroxyacetone phosphate were used as internal standards (see Table S5 ).
Chromatographic separation of intracellular organic acids was achieved on a reversed phase column (C18EVO, Phenomenex) connected to a guard column (SecurityGuard ULTRA cartridge, UHPLC C18EVO) at a constant flow of 0.2 ml/min and a temperature of 55 °C in gradient mode where solvent A was water:formic acid (99.9:0.1) and solvent B was acetonitrile:formic acid (99.9:0.1) according to the following profile: 0 -2 min, 0% B; 2 -4 min, 0 -95% B; 4 -8 min, 95% B; 8 -8.1 min, 0% B; 8.1 -15 min, 0% B. The injection volume of standards and samples was 1 µl and uniformly labelled 13 C-alpha-ketoglutarate (see 13 CAKG -Table S5 ) was used as an internal standard. A detailed description of instrument settings, accurate masses and mass transitions is given in Tables S4 and S5. PATIENTS INFORMATION Patient 1 (PT1) is a 6 year-old boy from Algeria, diagnosed at birth because of neonatal hypoglycemia. Glycogen Storage Disease type 1a was excluded genetically. Because of neutropenia, Glycogen Storage Disease type 1b (GSD1b = G6PT deficiency) was suspected. He had severe stomatitis, recurrent gastrostomy infections, but also nose bleeds because of platelet dysfunction. When the blood samples were taken for leucocyte analysis, treatment and care consisted of allopurinol (Zyloric®) and gavage of enriched maltose-dextrin milk and raw corn starch.
Patient 2 (PT2) is a 10 year-old girl of Russian origin. She presented with neonatal hypoglycemia and kernicterus requiring blood exchange transfusion. Glycogen Storage Disease type 1b was genetically confirmed (homozygous 1042delCT resulting in a frameshift after Ala347 and a premature stop codon). She was living donor liver transplanted (mother) at the age of 1 year and 2 months because of repetitive hypoglycemic episodes despite appropriate diet via gastrostomy. After liver transplantation, she was treated with G-CSF because of persisting neutropenia and recurrent stomatitis. When blood samples were taken for analysis, she was taking tacrolimus (Prograft®) every day and G-CSF (Neupogen®) twice a week.
Patient 3 (PT3) is a 10 year-old girl born in Romania after 35 weeks of gestation with intrauterine growth retardation. During the neonatal period she developed severe omphalitis with sepsis, and during the first year of life she suffered from recurrent pneumonia as well as skin infections (skin abscesses, cellulitis). Later, she suffered from episodes of severe aphthosis and was diagnosed with congenital heart defect with pulmonary hypertension, requiring surgical correction. She presented growth retardation during the first years of life, which improved over time. All the above symptoms, together with cutis laxa and the severe congenital neutropenia are characteristic of a deficiency of G6PC3. Despite this suspicion, G6PC3 deficiency was only genetically confirmed at the age of 7 years (homozygous 960del resulting in a frameshift after Leu319 and a premature stop codon). She required occasional G-CSF treatment following severe infections to raise neutrophil counts, but was not being treated when the blood sample that we analysed was taken. Figure S1 . The addition of a 6xHis tag to the N-or C-terminal ends of human recombinant G6PC1 or G6PC3 does not affect their preference to hydrolyze either glucose-6-phosphate and ribose-5-phosphate when proteins are expressed in HEK293T cells. Wild-type (WT) and catalytically inactive (H176A or H167A) human G6PC1 and G6PC3 were produced as recombinant proteins in HEK293T cells with a 6xHis tag in N-terminal (A and D) or in C-terminal (B and E) or with no tag (C and F). Equal amounts of the membrane fractions (respectively, 5 µg and 10 µg for N-and C-terminal tagged proteins) were analyzed by western blotting with an anti-6xHis antibody to ensure that expression of similarly tagged G6PC1 and G6PC3 was comparable. Since this was the case for these proteins, we assumed that it was also the case for the untagged ones. The membrane preparations were used at appropriate concentrations to assay the glucose-6-phosphatase (A-C) and the ribose-5-phosphatase (D-F) activity with 100 µM glucose-6-P or ribose-5-P through the release of inorganic phosphate. Phosphatase activity observed in preparations from cells expressing the catalytically dead mutants or transfected with an empty plasmid are also shown. Values shown are means ± SEM; n = 3.
SUPPLEMENTARY FIGURES AND LEGENDS

Figure S2. 1,5AG is present in wild-type, G6PC3 or G6PT deficient Hap1 cells cultured in the presence of 1,5-anhydroglucitol or of its precursor 1,5anhydrofructose.
This figure is a supplement to Fig. 2 in the main paper. Wild-type, G6PT deficient (clone A4) and G6PC3 deficient (clone D7 and A6) HAP1 cells were cultured for 24h in DMEM (1 g/l glucose) medium with or without addition of the indicated concentrations of 1,5AG (A) or 1,5-anhydrofructose (B). Growth medium was replaced after 20 h and approximately 4 h before the preparation of cell extracts. 1,5AG was analyzed by LC-MS. We cannot exclude that part of the 1,5AG detected in cells incubated with 1,5AG (A), does not result from extracellular contamination. However, it is clear that when increasing amounts of 1,5-anhydrofructose were added to the media, 1,5AG accumulated proportionally in these cells whether these were wild-type or G6PT or G6PC3 deficient (B). Values represent means ± SD of 3 independent experiments. TIC: Total Ion Current. Figure S3 . GC-MS analysis of G6PC3 or G6PT deficient HAP1 cell lines. 1,5anhydroglucitol-6-phosphate accumulates in cells cultured in the presence of 1,5anhydroglucitol or its precursor 1,5-anhydrofructose resulting in a decrease of glycolysis and pentose-phosphate pathway intermediates. This figure provides data from a targeted GC-MS analysis of the metabolome of the same HAP1 cell lines shown in Fig. 2 and cultured in a similar way. Wild-type, G6PT deficient (clone A4) and G6PC3 deficient (clone D7 and A6) HAP1 cells were cultured for 24h in DMEM (1 g/l glucose) medium with or without addition of the indicated concentrations of 1 ,5AG (A-B, E-G Fig. 4 , but performed on a younger mouse cohort (6 to 8 weeks old; 16 -20 g). Two groups of eight G6PC3 deficient mice were either treated with 100 µl suspension of Empagliflozin (10 mg/Kg in 0.9% NaCl; EMPA) or the same volume of saline (CT). The mice were treated 8 times in total: once on two consecutive days followed by two days of rest; the same protocol was repeated 3 times during a total period of 16 days. At this time mice were euthanized and blood was collected for analysis. (A) Blood 1,5AG was quantified from plasma recovered from EDTA-blood. (B) Granulocytes were estimated by flow cytometry analysis of white blood cells (WBC) from 50 µl of EDTA-blood double labeled with anti-Mac-1 (CD11b-PE) and anti-Gr1 (Ly-6G-FITC) antibodies as well as (C) based on total leucocyte counts from a SYMEX XL analyzer and neutrophils manual classification on DI60 a digital microscope. (D) LCMS analysis of 1,5AG6P in extracts from white blood cells isolated from the remaining blood collected; values shown are in arbitrary units (AU) and normalized to Total Ion Current (TIC). Statistical analysis: (A-D) p values were determined with an unpaired t test with Welch's correction without assuming a consistent SD (n = 8). Data are means and error bars are ± SD. ∍ p ≤ 0.01; $ p ≤ 0.0001. TIC: Total Ion Current.
Figure S5. Empagliflozin treatment reverses the neutrophil maturation arrest induced by 1,5-anhydroglucitol administration in G6PC3-deficient mice.
G6PC3-deficient mice were treated with 1,5AG (5 x 100 µl of 50 mM) during seven days. After which they were split in two groups (n = 4) that received either Empagliflozin (+EMPA -red symbols; 10 mg/kg in 100 µl 0.9% NaCl; five times over eight days) to lower plasma 1,5AG or vehicle (+ saline -open symbols). (A) Blood 1,5AG was monitored by LC-MS analysis of serum from 15 µl tail blood taken on the indicated days or from plasma of blood collected after euthanasia on day 15. After day 7, when administration of 1,5AG was stopped, blood 1,5AG either declined slowly in mice that were administered saline (open symbols) or declined sharply in those administered Empagliflozin (red symbols). (B) Flow cytometry of white blood cells (WBC) analysis showing Mac-1/Gr-1 labeled granulocytes was performed either on 25 µl of tail blood (days 0, 7 and 13) or on 50 µl of EDTA-blood collected after euthanasia. Mice treated with Empagliflozin show a strong and rapid increase in granulocyte numbers (see also  Table S2 ), which is in accordance with the images of the neutrophil-rich bone marrow aspirates of two Empagliflozin treated mice (D and F) and contrasts with the arrested, promyelocyte-rich aspirates from saline treated mice (C and E). The activities where assayed by measuring the Pi released and using recombinant proteins with a C-term 6xHis. (1) The "V max " values that are shown are "apparent V max " because the proteins are not purified. 15AG6P: 1,5-anhydroglucitol-6-phosphate PPi: inorganic pyrophosphate Data corresponds to means ± SEM (n ≥ 3) Immature granulocytes (%) 0.0 ± 0.0 9.4 ± 6.7
SUPPLEMENTARY TABLES
Eight 14-weeks old G6PC3-deficient female mice (21 to 25g) were gavaged with 5 doses of 100µl of 50 mM 1,5-anhydroglucitol (1,5AG) over 7 days and blood AG increased from 40,6 ± 4.1 (day 0) to 163.7 ± 32.6 (day 7). At day 8, mice were either gavaged with 5 doses of 10mg/kg of Emplagliflozin or with 100 µl of saline (0.9 % NaCl -the vehicle) over 9 days until sacrifice (see also Fig. S4 ). One mouse receiving saline died during the experiment.
On the day of sacrifice white blood cell (WBC) counts were obtained from a Sysmex XN1000 hematology analyzer and blood differentials come from manual reclassification on a Sysmex Di60 digital microscope. Immature granulocytes include promyelocytes, myelocytes and metamyelocytes. Data equals mean ± SD 
